All News
Filter News
Found 757,483 articles
-
Kyocera Develops New “Contactless Intelligent Millimeter-Wave Sensing System”
2/2/2023
Kyocera Corporation (President: Hideo Tanimoto) today announced it has developed a new “contactless intelligent millimeter-wave sensing system”.
-
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
2/2/2023
Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb in August 2021, has entered Phase 1 clinical trials in the United States.
-
Thermo Fisher Scientific to Power All Current U.S. Sites With 100 Percent Renewable Electricity
2/2/2023
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it will power all of the company’s current U.S. sites with 100 percent renewable electricity by 2026.
-
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 2, 2023
2/2/2023
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on February 1, 2023 as inducements material to each employee entering into employment with KalVista.
-
Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
2/2/2023
Oligomerix, Inc. today announced the dosing of its first subjects in the company’s Phase 1a clinical trial evaluating lead candidate OLX-07010.
-
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
2/2/2023
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022.
-
Volta Medical Announces Completion of Patient Enrollment in TAILORED-AF Clinical Trial for Treatment of Atrial Fibrillation
2/2/2023
Volta Medical today announced the completion of patient enrollment in the randomized controlled clinical trial, TAILORED-AF, evaluating VX1-guided ablation compared to a ‘standard of care’ anatomical ablation approach.
-
Singular Genomics Joins the 10x Genomics Compatible Partner Program
2/2/2023
Singular Genomics Systems, Inc. today announced its G4 Sequencing Platform demonstrated compatibility with the 10x Genomics’ Chromium Single Cell platform through the 10x Compatible Partner Program (CPP).
-
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
2/2/2023
Anavex Life Sciences Corp. today announced the total enrollment of 92 patients with Rett syndrome for the ANAVEX®2-73 ( blarcamesine ) EXCELLENCE Phase 2/3 study in Rett syndrome patients ages ≥ 5 years to 17 (inclusive).
-
Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.
2/2/2023
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement whereby Tonix has acquired all of the assets of Healion Bio, Inc. (Healion) including its entire portfolio of next-generation antiviral technology assets.
-
Vetter’s Clinical Facility Demonstrates Success with Five Client Products Now on the Market
2/2/2023
Both the US Skokie and European Rankweil sites address customer needs in early-phase drug development
-
PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome
2/2/2023
PharmaTher Holdings Ltd. today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to KETARX™ (racemic ketamine) for the treatment of Rett Syndrome, a rare genetic neurological disorder.
-
ROSALIND FRANKLIN UNIVERSITY STARTUP PREPARING FOR FDA IND FILING AND A PIVOTAL CLINICAL TRIAL ON NOVEL THERAPY FOR SUDDEN CARDIAC ARREST
2/2/2023
Rosalind Franklin University of Medicine and Science (RFU) announced today that one of its early-stage companies — Resuscitation Therapeutics (RTx), which is focused on developing new therapies for life-threatening acute cardiovascular events — is preparing an Investigational New Drug (IND) application for submission to the U.S. Food and Drug Administration proposing a novel treatment for sudden cardiac arrest (SCA).
-
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
2/2/2023
Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), today announced that Mr. James Foster , Chief Executive Officer of Virax, has issued a letter to shareholders.
-
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
2/2/2023
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).
-
Phase IIb Clinical Study of Investigational Compound Elinzanetant Evaluated Efficacy and Safety in Postmenopausal Patients with Vasomotor Symptoms Study Findings Published in Menopause: The Journal of The North American Menopause Society
2/2/2023
Menopause: The Journal of the North American Menopause Society today published “Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1),” detailing the results of the SWITCH-1 clinical trial aimed at identifying effective dosing for the investigational compound elinzanetant, a non-hormonal, selective neurokinin 1,3 receptor antagonist.
-
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic FibrosisPatient dosing expected to begin in mid-February with topline data anticipated by mid-2023
2/2/2023
First Wave BioPharma, Inc. today announced that the first patient was screened for the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).
-
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
2/2/2023
Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company") is pleased to announce it has completed its pre-Investigational New Drug ("IND") meeting with the U.S. Food and Drug Administration (FDA) and received positive feedback regarding the Company's development plans for a novel NeuroDirect™ topical formulation of ketamine, intended for treating post-traumatic stress disorder (PTSD).
-
Varian Receives FDA 510(k) Clearance for Halcyon and Ethos Radiotherapy Systems Featuring HyperSight Imaging Solution and Announces First Patient Treatment
2/2/2023
Varian, a Siemens Healthineers company, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), as well as CE mark, for Halcyon® and Ethos™ radiotherapy systems featuring Varian's HyperSight™ imaging solution.
-
Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs
2/2/2023
Mindset Pharma Inc. announced today that the United States Patent and Trademark Office (“USPTO”) has granted allowance for another of Mindset’s Family 1 patent applications, number 17/743,718, titled “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”